Cancer Chemotherapy and Pharmacology

Papers
(The H4-Index of Cancer Chemotherapy and Pharmacology is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Determination of 5-azacitidine in human plasma by LC–MS/MS: application to pharmacokinetics pilot study in MDS/AML patients110
Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions32
Quantitative proteomics profiling reveals the inhibition of trastuzumab antitumor efficacy by phosphorylated RPS6 in gastric carcinoma32
Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with 4hydroxycyclophosphamide formation in children with Cancer28
A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro26
Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study25
Pazopanib and antacids: insights from the WHO pharmacovigilance database25
EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer24
A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma23
Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy23
Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer19
Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma18
Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations18
Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration18
Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study17
Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms17
Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients17
Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review17
Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide17
Comment on “Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase”17
0.030120134353638